ClinicalTrials.gg
CompletedNCT04429191Updated Sep 28, 2026

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

A Phase 1 interventional study of Humanized anti-CD117 Monoclonal Antibody (JSP191) in MYELODYSPLASTIC SYNDROME; MDS and ACUTE MYELOID LEUKEMIA; AML, sponsored by Jasper Therapeutics, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Jasper Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2023, 3 years 5 months ago, and no results have been posted to the registry.
Updated Sep 28, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States — 312 open to participants now, 466 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Enrollment
999th of 1,907
32 · median 35
Started
2020
with 91 others
Phase 1
772 of 2,137
130 open now
Registered
1,678th of 2,137
by date

Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 999th largest by enrollment of the 1,907 interventional ones that give a count, is one of 92 that started in 2020, is one of 772 in phase 1, and was the 1,678th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

312 of the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

307 more — sign in →

All 312 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allogenic blood stem cell transplantation.

Read the detailed description

This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allogenic blood stem cell transplantation.

Blood Stem Cell transplantation offers the only potentially curative therapy for many forms of Acute Myeloid Leukemia (AML) and for Myelodysplastic Syndrome (MDS). While standard of care conditioning regimens given prior to blood Stem Cell transplantation, such as standard TBI/Flu conditioning are well tolerated, they are associated with increased rates of relapse due to persistence of disease causing Hematopoietic Stem Cells and insufficient graft versus leukemia effect.

The biological conditioning regimen JSP191 is an antibody that binds to CD117. CD117 is the receptor for Stem Cell Factor on blood forming cells. CD117 binding to Stem Cell Factor is critical for survival and maintenance of blood forming stem cells.

The binding of JSP191 to CD117 blocks CD117 from binding to Stem Cell Factor on blood forming stem cells. In the absence of CD117/Stem Cell Factor binding, hematopoietic stem cells that are currently occupying the bone marrow niches in MDS/AML patients are depleted.

This study will investigate the safety and tolerability of adding JSP191 (an anti-CD117 monoclonal antibody therapy) to standard TBI/Flu conditioning regimen in adults with AML and MDS undergoing hematopoietic stem cell transplant.

03

Conditions studied

  • MYELODYSPLASTIC SYNDROME; MDS
  • ACUTE MYELOID LEUKEMIA; AML

Keywords

  • ACUTE MYELOID LEUKEMIA
  • AML
  • MDS
  • MYELODYSPLASTIC SYNDROME
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • AML/MDS as defined by specific criteria, including but not limited to the following subtypes:

    1. AML in CR
    2. MDS \< 5% BM blasts
    3. MDS 5 - 10% BM blasts
    4. AML not in CR or MDS > 10% BM blasts
  • Patients with human leukocyte antigen (HLA) matched related or unrelated donors
  • Adequate end organ function as defined in study protocol

Key Exclusion Criteria:

  • Patients with any acute or uncontrolled infections
  • Patients receiving any other agents
  • Patients with active non-hematologic
  • Prior allogeneic hematologic cell transplantation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Blood Stem Cell Transplant w/ anti-CD117 conditioning

    The phase 1a portion of the study plans to assess approximately 3 planned dose cohorts of JSP191: 0.3 mg/kg, 0.6 mg/kg, and 1.0 mg/kg to determine the maximum tolerated dose for expansion. Subjects will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery. The phase 1b portion of the study will enroll additional subjects at the expansion dose in order to further explore the safety, feasibility, and PK of that dose.

    Biological: Humanized anti-CD117 Monoclonal Antibody (JSP191)

Interventions

06

What researchers measure

Primary outcomes

  1. The number of subjects experiencing adverse events and serious adverse events will be assessed.

    The number of subjects experiencing adverse events and serious adverse events will be assessed.

    Time frame: Up to 1 year post Donor Cell Transplant (28 days dose limiting toxicity period)

  2. The number of dose limiting toxicities will be assessed.

    The number of dose limiting toxicities will be assessed.

    Time frame: Up to 1 year post Donor Cell Transplant (28 days dose limiting toxicity period)

  3. The type of dose limiting toxicities will be assessed.

    The type of dose limiting toxicities will be assessed.

    Time frame: Up to 1 year post Donor Cell Transplant (28 days dose limiting toxicity period)

07

Study locations

6 sites
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
  • Stanford University
    Stanford, California 94305, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Huntsman Cancer Institute - University of Utah
    Salt Lake City, Utah 84112, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
08

References and documents

Publications

  • Muffly L, Lee CJ, Gandhi A, Varma A, Scott BL, Patel SS, Shiraz P, Youn M, Yanagiba C, Arulprakasam J, Le A, Kwon HS, Long-Boyle J, Shizuru JA, Pang WW, Artz AS. Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS. Blood. 2026 May 28;147(22):2610-2620. doi: 10.1182/blood.2025031858. PubMed 41785374 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Jun 2023, 35 months.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 35 months is below that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Oct 2023 → Jun 2023 and completion Dec 2023 → Jun 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2020
First posted
Jun 12, 2020
StartActual
Jul 8, 2020
Primary completionActual
Jun 13, 2023was Oct 2023
CompletionActual
Jun 13, 2023was Dec 2023
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Sep 28, 2026
Primary completion
Oct 15, 2023→Jun 13, 2023 (actual)
Sep 28, 2026
Study completion
Dec 8, 2023→Jun 13, 2023 (actual)
Sep 28, 2026
Enrollment
40 (estimated)→32 (actual)
Sep 28, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41785374 ↗
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Status unknown→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41785374 ↗
    Primary completion Oct 15, 2023→Jun 13, 2023 (now actual)
    Study completion Dec 8, 2023→Jun 13, 2023 (now actual)
    Enrollment 40 (estimated)→32 (actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04429191
Lead sponsor
Jasper Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 12, 2020
Start date
Jul 8, 2020
Primary completion
Jun 13, 2023
Completion
Jun 13, 2023
Last update
Sep 28, 2026

Study contacts

Lori Muffly, MD,MS
principal investigator · Stanford University
Andrew Artz, MD,MS
principal investigator · City of Hope Medical Center
Bart Scott, MD
principal investigator · Fred Hutchinson Cancer Center
Catherine Lee, MD
principal investigator · Huntsman Cancer Institute
Arpita Gandhi, MD
principal investigator · Oregon Health and Science University
Ankur Varma, MD,PhD
principal investigator · Rush University Medical Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Briquilimab

Start the discussion